Hatching a Procompetitive Settlement
Celeste Saravia of Cornerstone Research will join attorneys and a regulator at this webinar hosted by the Section of Antitrust Law of the American Bar Association.
Mergers in Life Sciences
In recent years, regulators have expanded their theories of potential anticompetitive harm from mergers in the life sciences industry.
Tevra Brands LLC v. Bayer Healthcare LLC
A jury awarded the defendant a complete victory at trial in this antitrust litigation involving allegations of anticompetitive exclusive dealing in the market for flea and tick medications.
Our Curious Amalgam: How Do We Measure Innovation?
In an American Bar Association podcast, Penka Kovacheva of Cornerstone Research discussed how M&A affects innovation in the pharmaceutical industry.
The Impact of Pharmaceutical M&A on Innovation
The authors examine existing academic literature on the impact of pharmaceutical mergers and acquisitions and identify remaining gaps.
ASHEcon 2024: The Annual Conference of the American Society of Health Economists
Cornerstone Research staff and affiliated experts will speak at this annual conference hosted by the American Society of Health Economics.
2024 Antitrust in Healthcare
James Lee of Cornerstone Research will discuss competition issues in healthcare and life sciences at this American Bar Association conference.
Entrenching and Leveraging Market Dominance in the 2023 Merger Guidelines: Insights from Amgen/Horizon
Insights from Amgen/Horizon merger on leveraging market dominance via bundling under 2023 Merger Guidelines.
How A 3-Firm ‘Joint Effort’ Beat A $3.6B Pharma Antitrust Suit
In this Law360 article, counsel discusses Celeste Saravia’s pivotal role as the economic expert in a pharmaceutical antitrust lawsuit.
Ciccio et al. v. SmileDirectClub LLC et al.
Class certification was denied in this false advertising matter.
Brussels Team Expands with Experienced Competition Hire
Dr. Norbert Maier joins Cornerstone Research, with deep antitrust law and competition expertise from the EU Commission DG COMP team.
5 Questions with Sayeh Nikpay: The 340B Drug Pricing Program
Professor Sayeh Nikpay of the University of Minnesota discusses the role and implementation challenges of the 340B Drug Pricing Program.
How can we help you?
If you are looking for a publication not on our website, contact us.